FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
- Pyzchiva® (ustekinumab-ttwe) is approved by FDA for all indications of reference medicine
- FDA granted provisional determination for interchangeability designation for Pyzchiva®
- Extends Sandoz immunology portfolio and further strengthens biosimilar position
- Expected to be among first wave of ustekinumab biosimilars to launch in US
Basel, July 1, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has approved biosimilar Pyzchiva®* (ustekinumab-ttwe) 45 mg/0.5 mL and 90 mg/mL pre-filled syringes for subcutaneous injection and 130 mg/26 mL (5 mg/mL) single-dose vial for intravenous infusion. Developed by Samsung Bioepis Co., Ltd, it is approved for all indications of its reference medicine and will be commercialized by Sandoz in the US. In addition, the FDA provisionally determined that Pyzchiva® would be interchangeable with the reference medicine as it is currently subject to an unexpired period of exclusivity for the first interchangeable biosimilar biological products.
Sandoz intends to launch Pyzchiva® in the US in February 2025, in accordance with the settlement and license agreement with Janssen Biotech Inc. previously announced by Samsung Bioepis Co., Ltd. Pyzchiva® is expected to be among the first wave of ustekinumab biosimilars to launch in the US.
Claire D'Abreu-Hayling, Chief Scientific Officer, Sandoz, said: “This approval reflects our dedication to ensuring high-quality treatments are universally accessible. By further expanding our immunology portfolio with affordable biosimilar alternatives, we continue to make significant strides towards achieving our goal of delivering life-changing medicines to the patients who need them.”
Pyzchiva® is a key biosimilar value driver for the company over the mid-term, and this approval is a major step in advancing the Sandoz growth strategy by extending the US immunology portfolio.
Pyzchiva® is approved by the FDA for all indications of the reference medicine Stelara®† (ustekinumab), a human interleukin (IL)-12 and IL-23 antagonist,1 including to treat adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease and moderately to severely active ulcerative colitis, as well as pediatric patients with moderate to severe plaque psoriasis and active psoriatic arthritis.2
Leah M. Howard, J.D., President and CEO of the National Psoriasis Foundation, said: "Systemic medications like biologics are a key treatment option for many people to manage symptoms of psoriasis and psoriatic arthritis. Unfortunately, barriers to care, including costs, often prevent patients from getting the drug they are prescribed. Psoriatic disease is lifelong and chronic, leading to long-term treatment costs. Having more FDA-approved options can help make appropriate healthcare more affordable.”
Plaque psoriasis is the most common form of psoriasis, affecting approximately 80% to 90% of patients.3
The FDA granted approval to Samsung Bioepis based on the totality of the evidence, including robust clinical studies confirming that Pyzchiva® has equivalent efficacy and comparable safety as its reference medicine.
Sandoz entered into a development and commercialization agreement for biosimilar ustekinumab with Samsung Bioepis in September 2023. Under the terms of the agreement, Sandoz has the right to commercialize Pyzchiva® in the US, Canada, the European Economic Area (EEA), Switzerland and the UK. Samsung Bioepis remains responsible for development, registration, intellectual property, manufacturing and supply.
*Pyzchiva® is a trademark of Samsung Bioepis Co. Ltd.
†Stelara® is a registered trademark of JOHNSON & JOHNSON (USA).
INDICATIONS
PYZCHIVA (ustekinumab-ttwe) is indicated for the treatment of patients 6 years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, patients 6 years or older with active psoriatic arthritis, adult patients with moderately to severely active Crohn’s disease, adult patients with moderately to severely active ulcerative colitis.
CONTRAINDICATIONS: Clinically significant hypersensitivity to ustekinumab or to any of the excipients.
WARNINGS AND PRECAUTIONS: Infections: Serious infections have occurred. Avoid starting PYZCHIVA during any clinically important active infection. If a serious infection or clinically significant infection develops, discontinue PYZCHIVA until the infection resolves. Theoretical Risk for Particular Infections: Serious infections from mycobacteria, salmonella and Bacillus Calmette-Guerin (BCG) vaccinations have been reported in patients genetically deficient in IL-12/IL-23. Consider diagnostic tests for these infections as dictated by clinical circumstances. Tuberculosis (TB): Evaluate patients for TB prior to initiating treatment with PYZCHIVA. Initiate treatment of latent TB before administering PYZCHIVA. Malignancies: Ustekinumab products may increase risk of malignancy. The safety of ustekinumab products in patients with a history of or a known malignancy has not been evaluated. Hypersensitivity Reactions: If an anaphylactic or other clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue PYZCHIVA. Posterior Reversible Encephalopathy Syndrome (PRES): If PRES is suspected, treat promptly and discontinue PYZCHIVA.
Immunizations: Avoid use of live vaccines in patients during treatment with PYZCHIVA. Noninfectious Pneumonia: Cases of interstitial pneumonia, eosinophilic pneumonia and cryptogenic organizing pneumonia have been reported during post-approval use of ustekinumab products. If diagnosis is confirmed, discontinue PYZCHIVA and institute appropriate treatment.
ADVERSE REACTIONS: Most common adverse reactions are Psoriasis (≥3%): nasopharyngitis, upper respiratory tract infection, headache, and fatigue. Crohn’s Disease, induction (≥3%): vomiting. Crohn’s Disease, maintenance (≥3%): nasopharyngitis, injection site erythema, vulvovaginal candidiasis/mycotic infection, bronchitis, pruritus, urinary tract infection, and sinusitis. Ulcerative colitis, induction (≥3%): nasopharyngitis. Ulcerative colitis, maintenance (≥3%): nasopharyngitis, headache, abdominal pain, influenza, fever, diarrhea, sinusitis, fatigue, and nausea.
This is not the complete list of all the safety information for PYZCHIVA. Please see full Prescribing Information for PYZCHIVA.
Disclaimer
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
References
1. Janssen Pharmaceuticals. Stelara® (Ustekinumab): Prescribing Information. Available at: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf [Last accessed: June 2024]
2. Pyzchiva®. Prescribing Information. Available at: BLA 761373 and BLA 761425 PI MG and IFU.pdf (sandoz.com) [Last accessed: June 2024]
3. Journal of the American Academy of Dermatology. Guidelines of Care for the Management Psoriasis and Psoriatic Arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Available at: https://www.jaad.org/article/S0190-9622(08)00273-9/fulltext [Last accessed: June 2024]
About Sandoz
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of more than 100 nationalities work together to ensure 800 million patient treatments are provided annually by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the first biosimilar in 2006. In 2023, Sandoz recorded sales of USD 9.6 billion.
Global Media Relations contacts | Investor Relations contacts |
Global.MediaRelations@sandoz.com | Investor.Relations@sandoz.com |
Joerg E. Allgaeuer +49 171 838 4838 |
Karen M. King +1 609 722 0982 |
Chris Lewis +49 174 244 9501 |
Laurent de Weck +41 79 795 7364 |
- Novotech 发布 2023 年血友病和原发性胆汁性胆管炎全球临床试验深度概况报告
- 节卡机器人登临ITES深圳工业展 以新质生产力下好智造升级“先手棋”
- 笔生灵韵·一鸣惊人——书画名家闫福旺百家媒体聚焦报道
- 上海临港耀华国际学校艺术展惊艳SNAP艺术中心
- 小柯剧场“「五」法「五」天「五十五」封”超值线索,揭开旧梦真相!
- 泰康人寿HWP为“3.15”消保代言
- Boomi将简化并加速向SAP Datasphere的迁移
- 黄记煌:二十年味蕾记忆的情感传承
- 报长春国际商务学院中外合作办学3+1全日制本科需要什么条件?
- 贵州融州华企业管理有限公司:专业化财税服务的新星
- 临商银行金雀山支行持续加强适老化服务
- 火星人集成灶智感科技,引领未来厨房新风尚
- World heading for a 3-degree C warming trajectory, as political headwinds slow the energy transition
- 珠海一荣报关代理高级认证企业-----澳门物流一条龙服务
- 品味佛山·乐行时分听歌会2024 4月14日再度唱响佛山
- Snail Inc. Unveils Release Date for Anticipated Title, Bellwright
- 东莞市莞瑞电子有限公司—超凡音质,为爱诠释
- 时光Classic演唱会•昆山站官宣 打造音乐品牌共谱文旅新画卷
- 携手中国养老网 —— 开启全球养老产业共赢新时代
- 【AVIO】超声波焊接在线束上的应用-上海亚哲代理AVIO
- 临商银行金雀山支行多措并举开展反电诈宣传活动
- INVNT™ ANNOUNCED AS SPONSOR AND CO-PRODUCER OF DISCOVERY STAGE AT SXSW SYDNEY® 2024
- 初心如磐•向新出发 | 2024智能家居UP峰会暨CSHIA智能家居开年盛典成功举办
- 刘诗诗爆剧后商业价值飙升,《狐妖小红娘竹业篇》片花美到惊艳
- 尚小标-智能AI商标注册交易平台【24小时您口袋里的商标管家】
- 解码“成都金融”之四:成都加快构建特色金融产业体系
- 鹏特资本进入中国市场具有以下一些优势
- Teledyne FLIR IIS announces a new modular and compact USB3 machine vision camera series
- 24h解锁“宝藏地图”:打卡杭州萧山最火的九条旅行线路
- FILTERS滤镜之谜面膜或代表泰国史上最高护肤标准面膜!
推荐
- 新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
- 透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 抖音直播“新红人”进攻本地生活领域 不难看出,抖音本地生活正借由直播向本地生活 资讯
- 国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯
- 产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯
- 奥运冠军刘翔更新社交账号晒出近照 时隔473天更新动态! 2月20日凌晨2点,奥运冠军刘翔更新社交账号晒 资讯
- 海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯
- 一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯